Sublingual Misoprostol versus Intramuscular Oxytocin for Prevention of Postpartum Hemorrhage in Uganda: A Double-Blind Randomized Non-Inferiority Trial

English version České info

Background:
Postpartum hemorrhage (PPH) is a leading cause of maternal death in sub-Saharan Africa. Although the World Health Organization recommends use of oxytocin for prevention of PPH, misoprostol use is increasingly common owing to advantages in shelf life and potential for sublingual administration. There is a lack of data about the comparative efficacy of oxytocin and sublingual misoprostol, particularly at the recommended dose of 600 µg, for prevention of PPH during active management of labor.

Methods and Findings:
We performed a double-blind, double-dummy randomized controlled non-inferiority trial between 23 September 2012 and 9 September 2013 at Mbarara Regional Referral Hospital in Uganda. We randomized 1,140 women to receive 600 µg of misoprostol sublingually or 10 IU of oxytocin intramuscularly, along with matching placebos for the treatment they did not receive. Our primary outcome of interest was PPH, defined as measured blood loss ≥500 ml within 24 h of delivery. Secondary outcomes included measured blood loss ≥1,000 ml; mean measured blood loss at 1, 2, and 24 h after delivery; death; requirement for blood transfusion; hemoglobin changes; and use of additional uterotonics.

At 24 h postpartum, primary PPH occurred in 163 (28.6%) participants in the misoprostol group and 99 (17.4%) participants in the oxytocin group (relative risk [RR] 1.64, 95% CI 1.32 to 2.05, p<0.001; absolute risk difference 11.2%, 95% CI 6.44 to 16.1). Severe PPH occurred in 20 (3.6%) and 15 (2.7%) participants in the misoprostol and oxytocin groups, respectively (RR 1.33, 95% CI 0.69 to 2.58, p = 0.391; absolute risk difference 0.9%, 95% CI −1.12 to 2.88). Mean measured blood loss was 341.5 ml (standard deviation [SD] 206.2) and 304.2 ml (SD 190.8, p = 0.002) at 2 h and 484.7 ml (SD 213.3) and 432.8 ml (SD 203.5, p<0.001) at 24 h in the misoprostol and oxytocin groups, respectively. There were no significant differences between the two groups in any other secondary outcomes. Women in the misoprostol group more commonly experienced shivering (RR 1.91, 95% CI 1.65 to 2.21, p<0.001) and fevers (RR 5.20, 95% CI 3.15 to 7.21, p = 0.005).

This study was conducted at a regional referral hospital with capacity for emergency surgery and blood transfusion. High-risk women were excluded from participation.

Conclusions:
Misoprostol 600 µg is inferior to oxytocin 10 IU for prevention of primary PPH in active management of labor. These data support use of oxytocin in settings where it is available. While not powered to do so, the study found no significant differences in rate of severe PPH, need for blood transfusion, postpartum hemoglobin, change in hemoglobin, or use of additional uterotonics between study groups. Further research should focus on clarifying whether and in which sub-populations use of oxytocin would be preferred over sublingual misoprostol.

Trial registration:
ClinicalTrials.gov NCT01866241

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Sublingual Misoprostol versus Intramuscular Oxytocin for Prevention of Postpartum Hemorrhage in Uganda: A Double-Blind Randomized Non-Inferiority Trial. PLoS Med 11(11): e32767. doi:10.1371/journal.pmed.1001752
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001752

Souhrn

Trial registration:
ClinicalTrials.gov NCT01866241

Please see later in the article for the Editors' Summary

Zdroje

1. World Health Organization, United Nations Children's Fund, United Nations Population Fund, World Bank (2012) Trends in maternal mortality: 1990–2010. WHO, UNICEF, UNFPA and The World Bank estimates. Geneva: World Health Organization.

2. United Nations Department of Economic and Social Affairs Population Division (2013) World population prospects: the 2012 revision. New York: United Nations Department of Economic and Social Affairs Population Division.

3. Uganda Ministry of Health (2010) Clinical guidelines for prevention and treatment of post partum haemorrhage using misoprostol. Kampala: Uganda Ministry of Health.

4. World Health Organization (2012) WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: World Health Organization.

5. PrataN, BellS, WeidertK (2013) Prevention of postpartum hemorrhage in low-resource settings: current perspectives. Int J Womens Health 5: 737–752 doi:10.2147/IJWH.S51661

6. AtukundaEC, BrhlikovaP, AgabaAG, PollockAM (2013) Registration, procurement, distribution, and use of misoprostol in Uganda: an interview-based observational study. Lancet 382: 10.

7. StantonCK, NewtonS, MullanyLC, CofieP, Tawiah AgyemangC, et al. (2013) Effect on postpartum hemorrhage of prophylactic oxytocin (10 IU) by injection by community health officers in Ghana: a community-based, cluster-randomized trial. PLoS Med 10: e1001524.

8. TangOS, Gemzell-DanielssonK, HoPC (2007) misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 99 (Suppl 2) S160–S167.

9. Katzung GB (2010) Basic principles of pharmacology. In: Katzung GB, Masters SB, Trevor AJ, editors. Basic and clinical pharmacology, 12th edition. New York: McGraw-Hill Medical.

10. International Federation of Gynecology and Obstetrics (2012) Prevention of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet 119: 213–214 doi:10.1016/j.ijgo.2012.09.002

11. TuncalpO, HofmeyrGJ, GulmezogluAM (2012) Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 8: CD000494 doi:10.1002/14651858.CD000494.pub4

12. ChuCS, BrhlikovaP, PollockAM (2012) Rethinking WHO guidance: review of evidence for misoprostol use in the prevention of postpartum haemorrhage. J R Soc Med 105: 336–347 doi:10.1258/jrsm.2012.120044

13. DermanRJ, KodkanyBS, GoudarSS, GellerSE, NaikVA, et al. (2006) Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. Lancet 368: 1248–1253 doi:10.1016/S0140-6736(06)69522-6

14. MobeenN, DurocherJ, ZuberiN, JahanN, BlumJ, et al. (2011) Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in homebirths in Pakistan: a randomised placebo-controlled trial. BJOG 118: 353–361.

15. GulmezogluAM, VillarJ, NgocNT, PiaggioG, CarroliG, et al. (2001) WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 358: 689–695.

16. BaskettTF, PersadVL, CloughHJ, YoungDC (2007) Misoprostol versus oxytocin for the reduction of postpartum blood loss. Int J Gynaecol Obstet 97: 2–5 doi:10.1016/j.ijgo.2006.12.016

17. VaidA, DadhwalV, MittalS, DekaD, MisraR, et al. (2009) A randomized controlled trial of prophylactic sublingual misoprostol versus intramuscular methyl-ergometrine versus intramuscular 15-methyl PGF2alpha in active management of third stage of labor. Arch Gynecol Obstet 280: 893–897.

18. VimalaN, MittalS, KumarS (2006) Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynaecol Obstet 92: 106–110.

19. VimalaN, MittalS, KumarS, DadhwalV, MehtaS (2004) Sublingual misoprostol versus methlergometrine for active management of third stage of labor. Int J Gynaecol Obstet 87: 1–5.

20. Uganda Ministry of Health (2010) Uganda clinical guidelines: national guidelines on management of common conditions. Kampala: Uganda Ministry of Health.

21. BelladMB, TaraD, GanachariMS, MallapurMD, GoudarSS, et al. (2012) Prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind randomised controlled trial. BJOG 119: 975–982 doi:10.1111/j.1471-0528.2012.03341.x

22. HojL, CardosoP, NielsenBB, HvidmanL, NielsenJ, et al. (2005) Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial. BMJ 331: 723 doi:10.1136/bmj.331.7519.723

23. PiaggioG, ElbourneD, PockockSJ, EvansSJ, AltmanDG, et al. (2012) Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308: 2594–2604.

24. WesthoffG, CotterAM, TolosaJE (2013) Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database Syst Rev 10: CD001808 doi:10.1002/14651858.CD001808.pub2

25. NordstromL, FogelstamK, FridmanG, LarssonA, RydhstroemH (1997) Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. Br J Obstet Gynaecol 104: 781–786.

26. AltmanDG, SchulzKF, MoherD, EggerM, DavidoffF, et al. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663–694.

27. TewatiaR, RaniS, SrivastavU, MakhijaB (2014) Sublingual misoprostol versus intravenous oxytocin in prevention of post-partum hemorrhage. Arch Gynecol Obstet 289: 739–742.

28. ChaudhuriP, BiswasJ, MandalA (2012) Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in low-risk women. Int J Gynaecol Obstet 116: 138–142 doi:10.1016/j.ijgo.2011.09.016

29. WeeksA (2012) Commentary on “prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind, randomised controlled trial”. BJOG 119: 982–983.

30. LamH, TangOS, LeeCP, HoPC (2004) A pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor. Acta Obstet Gynecol Scand 83: 650.

31. ElatiA, WeeksA (2012) Risk of fever after misoprostol for the prevention of postpartum hemorrhage: a meta-analysis. Obstet Gynecol 120: 1140–1148.

32. DurocherJ, BynumJ, LeonW, BarreraG, WinikoffB (2010) High fever following postpartum administration of sublingual misoprostol. BJOG 117: 845–852 doi:10.1111/j.1471-0528.2010.02564.x

33. AmantF (2001) The misoprostal third stage study: a randomised controlled comparison between orally administered misoprostol and standard management. A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage labour. BJOG 108: 338.

34. BabinszkiA, KerenyiT, TorokO, GraziV, LapinskiRH, et al. (1999) Perinatal outcome in grand and great-grand multiparity: effects of parity on obstetric risk factors. Am J Obstet Gynecol 181: 669–674.

35. TsuVD (1993) Postpartum haemorrhage in Zimbabwe: a risk factor analysis. Br J Obstet Gynaecol 100: 327–333.

36. StonesRW, PatersonCM, SaundersNJ (1993) Risk factors for major obstetric haemorrhage. Eur J Obstet Gynecol Reprod Biol 48: 15–18.